Evidence map›Paper›PMID 35428310›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Reactive oxygen species-inducing titanium peroxide nanoparticles as promising radiosensitizers for eliminating pancreatic cancer stem cells.

Mohammed Salah, Hiroaki Akasaka, Yasuyuki Shimizu, Kenta Morita, Yuya Nishimura, Hikaru Kubota, Hiroki Kawaguchi, Tomomi Sogawa, Naritoshi Mukumoto, Chiaki Ogino and 1 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Advanced drug delivery platforms target cancer stem cells.Asian journal of pharmaceutical sciences · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cancer stem cell fate determination: mito-nuclear communication.Cell communication and signaling : CCS · 2023
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohammed SalahDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan. salah-Bio@vet.svu.edu.eg.
Hiroaki AkasakaDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Yasuyuki ShimizuDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Kenta MoritaDepartment of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Kobe, Hyogo, 650-0017, Japan.
Yuya NishimuraDepartment of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Kobe, Hyogo, 650-0017, Japan.
Hikaru KubotaDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Hiroki KawaguchiDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Tomomi SogawaDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Naritoshi MukumotoDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Chiaki OginoDepartment of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Kobe, Hyogo, 650-0017, Japan.
Ryohei SasakiDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan. rsasaki@med.kobe-u.ac.jp.

Funding

Ministry of Education, Culture, Sports, Science, and Technology of Japan 19K08121Ministry of Education, Culture, Sports, Science, and Technology of Japan 20K08134Ministry of Education, Culture, Sports, Science, and Technology of Japan 21K07594, 20KK0192, 20K21576, 20K08108
6 · The paper itself

Abstract

backgroundDespite recent advances in radiotherapy, radioresistance in patients with pancreatic cancer remains a crucial dilemma for clinical treatment. Cancer stem cells (CSCs) represent a major factor in radioresistance. Developing a potent radiosensitizer may be a novel candidate for the eradication of pancreatic CSCs.

methodsCSCs were isolated from MIA PaCa-2 and PANC1 human pancreatic cancer cell lines. Titanium peroxide nanoparticles (TiOxNPs) were synthesized from titanium dioxide nanoparticles (TiO

resultsIt is shown that TiOxNPs combined with ionizing radiation exhibit anti-cancer effects on radioresistant CSCs both in vitro and in vivo. TiOxNPs exhibited a synergistic effect with radiation on pancreatic CSC-enriched spheres by downregulating self-renewal regulatory factors and CSC surface markers. Moreover, combined treatment suppressed epithelial-mesenchymal transition, migration, and invasion properties in primary and aggressive pancreatic cancer cells by reducing the expression of proteins relevant to these processes. Notably, radiosensitizing TiOxNPs suppressed the growth of pancreatic xenografts following primary or dissociating sphere MIA PaCa-2 cell implantation. It is inferred that synergy is formed by generating intolerable levels of reactive oxygen species (ROS) and inactivating the AKT signaling pathway.

conclusionsOur data suggested the use of TiOxNPs in combination with radiation may be considered an attractive therapeutic strategy to eliminate pancreatic CSCs.

Indexed as

NanoparticlesPancreatic NeoplasmsRadiation-Sensitizing AgentsCell Line, TumorHumansNeoplastic Stem CellsPeroxidesReactive Oxygen SpeciesTitaniumPeroxidesRadiation-Sensitizing AgentsReactive Oxygen SpeciesTitaniumAKTPancreatic cancer stem cellsRadioresistanceRadiosensitizersReactive oxygen speciesTitanium peroxide nanoparticles

Identifiers

PMID35428310
PMCPMC9013114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.